News
DHR-PRB
1261.26
0.00%
0.00
Danaher completes acquisition of Masimo
PUBT · 06/10 12:56
DANAHER - DOES NOT EXPECT MATERIAL MASIMO CONTRIBUTION IN Q2 2026
Reuters · 06/10 12:56
BUZZ-SiriusXM rises on S&P MidCap 400 inclusion
Reuters · 06/09 09:41
S&P DOW JONES INDICES : MASIMO TO BE REMOVED FROM S&P MIDCAP 400 EFFECTIVE JUNE 11
Reuters · 06/08 22:10
Danaher enters note purchase agreement for CHF 2.38 billion senior notes private placement
PUBT · 06/03 20:35
U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty
Reuters · 06/03 07:55
DANAHER CORPORATION <DHR.N> : HSBC CUTS TARGET PRICE TO $230 FROM $270
Reuters · 06/03 05:18
SCIEX, Danaher unit, launches novus V55 triple quadrupole mass spectrometer
PUBT · 06/01 18:01
SCIEX expands ZenoTOF line with OS 5.0 software updates at ASMS
PUBT · 06/01 18:00
Illumina teams with IDT to offer DRAGEN-powered secondary analysis for oncology sequencing workflows
PUBT · 06/01 12:58
DANAHER CORP <DHR.N>: CITIGROUP RESUMES COVERAGE WITH BUY RATING; PRICE TARGET $230
Reuters · 05/27 10:15
U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys
Reuters · 05/27 08:06
MEDIA-Danaher raises $3 billion in record private-placement bond sale - Bloomberg News
Reuters · 05/22 20:36
China's commerce ministry holds meeting with foreign pharmaceutical firms
Reuters · 05/22 13:21
ALDEVRON: CO AND MINARIS RENEW LENTIVIRAL PLASMID AGREEMENT TO ACCELERATE GENE-MODIFIED CELL THERAPY DEVELOPMENT
Reuters · 05/11 11:34
Danaher shareholders approve amended omnibus incentive plan at annual meeting
PUBT · 05/07 21:54
Danaher CEO Blair to present at Bank of America Securities Health Care Conference
PUBT · 05/06 20:54
DANAHER CORP - DECLARES QTRLY CASH DIVIDEND OF $0.40 PER SHARE PAYABLE JULY 31, 2026
Reuters · 05/05 20:30
Danaher director Alan G. Spoon sells 1,358 shares for $237,609.87
PUBT · 05/04 21:01
BRIEF-Masimo Shareholders Approve Acquisition By Danaher
Reuters · 05/04 13:03
More
Webull provides a variety of real-time DHR-PRB stock news. You can receive the latest news about Danaher Corp through multiple platforms. This information may help you make smarter investment decisions.
About DHR-PRB
Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company’s segments include Biotechnology, which includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services; Life Sciences segment, which offers a range of instruments and consumables that are primarily used by customers to study the basic building blocks of life, including genes, proteins, metabolites, and cells, to understand the causes of disease, identify new therapies, and test and manufacture new drugs and vaccines; Diagnostics segment that offers clinical instruments, reagents, consumables, software, and services that hospitals, physicians’ offices, reference laboratories, and other critical care settings use to diagnose disease, and Environmental & Applied Solutions segment, which offers products and services that help protect precious resources and keep global food and water supplies safe.